American biopharmaceutical company in Cambridge, Massachusetts, founded in 2007 out of research on cancer metabolism and listed on Nasdaq, now devoted to rare blood diseases after selling its oncology business to Servier in 2021. Develops medicines that act on cellular metabolism, with the pyruvate kinase activator mitapivat sold as Pyrukynd for pyruvate kinase deficiency and studied in thalassaemia and sickle cell disease, and further pyruvate kinase and metabolic programmes in earlier development.
Aucun commentaire disponible.
Laissez votre note & commentaire